Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Ensayo abierto de seguridad y tolerabilidad a largo plazo de nintedanib oral, añadido al tratamiento estándar, durante al menos

Ensayo abierto de seguridad y tolerabilidad a largo plazo de nintedanib oral, añadido al tratamiento estándar, durante al menos 2 años, en niños y adolescentes con Enfermedad Pulmonar Intersticial fibrosante clínicamente significativa (InPedILD™-ON)

Contact
  • Protocol code: 1199-0378
  • EudraCT code: 2020-005554-23
  • Pathology: Enfermedad Pulmonar Intersticial
  • Pharmac: Nintedanib
  • Promoter: Boehringer Ingelheim España, S.A
  • Principal investigator:  Moreno Galdó, Antonio
  • Research group:  Creixement i desenvolupament
  • Service: Al·lergologia i Pneumologia pediàtrica
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Cerrado

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.